Navigation Links
Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
Date:7/27/2012

DEERFIELD, Ill. and OSAKA, Japan, July 27, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., resubmitted New Drug Applications (NDAs) to the United States (U.S.) Food and Drug Administration (FDA) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone. Takeda anticipates that these applications will be reviewed within the next six months. These NDAs were resubmitted in response to the complete response letter Takeda received from the FDA, dated April 25, 2012.

"Takeda was able to respond to the FDA promptly with significant new data from our ongoing clinical trial program and updated postmarketing data from outside the U.S.," said David Recker, M.D., senior vice president, clinical science, Takeda Global Research & Development Center, Inc. "Based on our meeting with the FDA in late June, Takeda believes the information included in the NDA resubmissions for alogliptin and the fixed-dose combination alogliptin and pioglitazone will address the Agency's request for additional data, and these investigational therapies remain a top priority for the company."

This 2012 resubmission includes additional data from three phase 3 clinical trials involving more than 3,275 patients conducted at 1,384 centers worldwide. When combined with previously submitted phase 3 clinical data, which included more than 8,000 patients conducted in more than 1,000 centers worldwide, nearly 10,000 patients have been treated with alogliptin in the clinical development programs to date.

Alogliptin is a selective dipeptidyl peptidase-4 inhibitor (DPP-4i) under investigation in the U.S. for the treatment of type 2 diabetes as an adjunct to diet and exercise. Alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play roles in r
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
3. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
4. Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan
5. Radiotherapy Devices Market By Technology, Applications & Products (2011 - 2016)
6. Frost & Sullivan: Label-Free Technology is a High Potential Market with Myriad Unexplored Applications
7. New Wireless Keyboard Rechargeable, Washable for Healthcare Applications
8. New, Affordable Flow Cytometer Cell Sorter Expands Access to Wider Range of Life Science Applications
9. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
10. Clinical Safety Data for ChromaDex®s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
11. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015  AccuTec Blades, Inc. today announced the ... division.  EPC announced in May 2015 its intent to ... Virginia and Obregon, Mexico ... process. Rick Gagliano , the ... said, "Our new name, AccuTec Blades, reflects the precision ...
(Date:9/1/2015)... and OR YEHUDA, Israel , ... (Nasdaq: HTWR ), a leading innovator of less ... treatment of advanced heart failure, announced today that it ... Valtech Cardio, Ltd . ("Valtech").  Valtech is a privately ... surgical and transcatheter valve repair and replacement devices for ...
(Date:9/1/2015)... and BRUSSELS , Sept. ... and UCB (Euronext Brussels: UCB) today announced top-line ... of RomosozUmab Compared with Teriparatide in postmenopaUsal women ... treated with bisphosphonatE therapy). The study (NCT01796301) met ... in favor of romosozumab in the percent change ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9
... , Breakthrough sample preparation instrument ... laboratories to eliminate many manual steps , ... transferring clinical samples from closed primary vials to compatible tubes ... launch in the U.S. started in late 2011, rollout under ...
... EAST BRUNSWICK, N.J., Jan. 5, 2012  Savient Pharmaceuticals, Inc. (NASDAQ: ... Executive Vice President and Chief Financial Officer of Savient ... Annual Equity Conference on Tuesday, January 17, 2012 at ... at the Seminole Hard Rock Hotel in Hollywood, Florida. ...
Cached Medicine Technology:QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System 2QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System 3QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System 4Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference 2
(Date:9/1/2015)... ... September 01, 2015 , ... OncLive® today announced ... News & World Report, to provide breaking news and information about the hospital’s ... within OncLive, which provides oncologists resources and information?they need to deliver the best ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider of an ... and activity, today announced its integration with leading veterinary Practice Management Software vendor ... hospital Practice Management Software packages in the US. Practice Management Software helps veterinarians ...
(Date:9/1/2015)... ... 2015 , ... e-Spirit Inc., a leading supplier of content ... Management System with new capabilities and enhancements designed to support the recently announced ... well on their way to achieving digital transformation with less time and less ...
(Date:9/1/2015)... ... 01, 2015 , ... WorkCare, Inc., a national occupational health ... team as an Associate Medical Director. , WorkCare specializes in workforce health ... and abroad. , Dr. Nelson has a diverse background. He trained in ...
(Date:9/1/2015)... Diego, CA (PRWEB) , ... September 01, 2015 , ... ... are just a few of the topics to be discussed at Seedstock’s 4th Annual ... Nov. 3-4, 2015, at UC San Diego. , In addition to keynotes Pierre ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5
... National AIDS Control Organization (NACO) of India plans to ... against HIV/AIDS//. The third phase of the National AIDS ... April. , Statistics show that approx. 80 ... for outpatient care and over 50 per cent for ...
... in certain patients following a liver transplant. A new study ... all the risk factors can be detected before a transplant ... risk ,They found the risk factors - a ... (HCV) paired with the use of a particular immunosuppressant- increase ...
... for Disease Control and Prevention (CDC) Atlanta's Division of ... changed its guidelines// and made TB tests mandatory for ... been residing there. ,Tuberculosis can only be ... tested and, if necessary, treated for latent TB infection, ...
... research published in the Jan. 10 issue of the ... chemists// and North Carolina State University toxicologists, finds that ... ,This research was based on the In-Vitro ... amino acids. "Our results confirm that repetitive motion ...
... for schools and nearly 20,000 students stayed home following fears ... to encephalitis two weeks ago. ,Dr. David Gifford, ... the parents' concerns and our concerns, we felt that out ... the next two days. Calling it an outbreak at the ...
... Bush has undergone a hip replacement surgery and is ... went well, the Mayo Clinic in Rochester, Minnesota said ... the father of the current president. His surgery came ... state funeral of former president Gerald Ford, who died ...
Cached Medicine News:Health News:Risk Factors That Cause NODM After A Liver Transplant 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2Health News:A Study Explores the Medical Potentials of Bucky Amino Acids 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: